CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,229 enrolled
Drug / intervention
Age 60+ with planned HCT for Hematologic Malignancyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03992352
NCT03992352N/ACompleted
CompareCT.gov

Composite Health Assessment Risk Model (CHARM) for Older Adults: Applying Pre-Transplant Comorbidity, Geriatric Assessment, and BioMarkers on Non-Relapse Mortality After Allogeneic Transplant (BMT CTN 1704)

Center for International Blood and Marrow Transplant Research·observational·Posted Jun 20, 2019·Updated Feb 6, 2024

In Brief

An observational study evaluating Age 60+ with planned HCT for Hematologic Malignancy for Hematologic Malignancy. Completed, enrolled 1,229 participants across 50 sites.

Detailed Summary

Prospective observational multicenter study of allogeneic Hematopoietic Stem Cell Transplantation (HCT) in recipients 60 years and older to assess important determinants of health status to be combined into a composite health risk model to improve risk assessment of non-relapse mortality (NRM).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Malignancy
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), Blood and Marrow Transplant Clinical Trials Network, National Marrow Donor Program

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJun 20, 2019
Enrollment StartJul 19, 2019
Primary CompletionMay 29, 2023
Study CompletionMay 30, 2023
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 7.0 years ago

Interventions

Age 60+ with planned HCT for Hematologic Malignancyother

questionnaires, geriatric assessments